VKVikram Khurana

Vikram Khurana

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Vikram Khurana has a total of 514 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Skin Seed Amplification Assay Differentiates Multiple System Atrophy from Parkinson's Disease

    by Anastasia Kuzkina, Diego Rodriguez, Celine Panzer, Alain Ndayisaba, Antonia Kohl, Shreya Rai, Breelyn Gilbert, Bruno Hammerschlag, Karie Shen, Lisa Harder‐Rauschenberger, et al.

    Background: Misdiagnoses of multiple system atrophy (MSA) and Parkinson's disease (PD) remain common. Objective: The objective of the study was to develop a skin α‐synuclein seed amplification assay (αSyn‐SAA) for detecting pathological α‐synuclein and distinguishing MSA from PD. Methods: In this blinded, cross‐sectional study, 308 skin biopsies from 117 participants were analyzed using a standardized thioflavin T fluorescence‐based αSyn‐SAA protocol. The cohort included 42 PD, 31 MSA, 30 controls, and 14 progressive supranuclear palsy (PSP) cases. Kinetic parameters were analyzed to differentiate PD from MSA, and matched skin cerebrospinal fluid (CSF)/magnetic resonance imaging (MRI) analyses were performed. Assay thresholds were predefined using brain lysates from neuropathologically confirmed cases. Fibril morphology from amplified skin samples was compared to postmortem brain using proteinase K digestion and electron microscopy. Results: αSyn‐SAA detected synucleinopathy (PD or MSA) with 82.2% sensitivity and 90% specificity versus controls. Receiver operating characteristic (ROC) analysis showed that maximum fluorescence ( F max , area under the curve [AUC] = 0.93) and lag time (AUC = 0.91) distinguished PD from MSA at the biopsy level. SAA positivity correlated with rapid eye movement (REM) sleep behavior disorder (RBD) in both disorders. Among SAA‐positive cases, the 50% mean F max cutoff correctly classified the underlying synucleinopathy in 81.7% of cases (49 of 60). Disease‐specific kinetic and structural signatures were reproducible across laboratories and αSyn substrate batches and were supported by concordant findings in a subset of skin samples matched to CSF, MRI data, and postmortem brain tissue. Conclusion: Skin αSyn‐SAA detects pathological α‐synuclein in living patients with high accuracy and distinguishes MSA from PD based on assay kinetics and fibril strain properties, supporting its potential as a biomarker to distinguish among synucleinopathies. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

  • Open Access

    A Humanized Mouse Model of DRPLA Recapitulates Epilepsy and Demonstrates Antisense Oligonucleotide-Mediated Disease Modification

    by Qian Wu, Inga Erickson, Stephanie Davidson, Sophie Shonka, Velvet Smith, Bereket Gidi, Kevin M Knox, Tim Yu, Vikram Khurana, Jeff Carroll, et al.

    Dentatorubral-pallidoluysian atrophy (DRPLA) is an ultra-rare progressive myoclonus epilepsy caused by a glutamine-coding CAG repeat expansion in atrophin-1 ( ATN1 ). Mutant ATN1 (m ATN1 ) expression results in symptoms that inversely correlate to CAG-expansion size: young-onset cases have the most CAG repeats and developmental delay, high-frequency treatment-resistant seizures, and early mortality. We sought to characterize the seizure susceptibility of a fully humanized ATN1 mouse expressing human m ATN1 with 112 CAG repeats to then assess therapeutic antisense oligonucleotide (ASO) intervention on seizure-related outcomes. Atn1 Q112/+ or wild-type (WT) mice were treated with investigational ASO targeting human, CAG-expanded, ATN1 or saline (P2 and then again at 4 weeks-old) before acute seizure testing, ataxia profiling, and chronic in vivo video-EEG recording for spontaneous seizures up to 8 weeks-old. Saline-treated Atn1 Q112/+ mice were more seizure prone with early death. However, ASO administration to Atn1 Q112/+ mice normalized seizure threshold, decreased ataxia, and protected against early death. Atn1 Q112/+ mice exhibited spontaneous behavioral seizures recorded over 2 weeks, which were absent in ASO-treated Atn1 Q112/+ and WT mice, with a specific m ATN1 expression-driven decrease in delta and theta EEG frequencies. Atn1 Q112/+ mice are highly seizure prone, validating this model for DRPLA epilepsy. ATN1 represents a novel epilepsy-related risk factor for therapeutic investigation.

  • Open Access

    Assessing AI and Neurologist Diagnostic Reasoning Against Neuropathological Ground Truth

    by Yu Leng, Ayush Noori, John R. Dickson, Alberto Serrano-Pozo, Marina Avetisyan, Diego Rodriguez, Eric S. Rosenberg, Yingnan He, Derek H. Oakley, Vikram S. Khurana, et al.

    BACKGROUND Accurate differential diagnosis of complex neurological disorders remains challenging due to overlapping clinical features and heterogeneous disease presentations. Although large language models (LLMs) show promise in clinical reasoning, prior studies benchmark performance against clinician consensus rather than biological ground truth. A neuropathologically confirmed benchmark dataset for evaluating diagnostic AI in neurology is currently lacking. METHODS We introduce NeuroBench, a curated benchmark of complex neurological cases with neuropathologically confirmed gold-standard diagnoses, and DIAGNO, a confidence-aware LLM-based system for neurological diagnosis. NeuroBench comprises 203 retrospective case summaries from the Massachusetts General Hospital Brain Cutting Conference with corresponding autopsy-confirmed diagnoses. DIAGNO generated top-3 differential diagnoses, employing retrieval-augmented generation (RAG) for lower-confidence cases. Performance was assessed by three independent blinded adjudicators who evaluated both DIAGNO and neurologists against neuropathological ground truth. RESULTS NeuroBench encompassed 79 unique neuropathological diagnoses, spanning conditions including cerebrovascular disease, brain tumors, neurological infections, and various neurodegenerative and inflammatory disorders. DIAGNO matched or outperformed neurologists in top-3 accuracy (0.67 versus 0.63) and taxonomy-level accuracy (0.74 versus 0.66). In cases of disagreement, DIAGNO was more often correct than neurologists (29 versus 19 cases). Diagnostic concordance between DIAGNO and neurologists was high (90% agreement in top-3 predictions), even when both were incorrect, suggesting strong alignment in diagnostic reasoning. On NeuroBench, DIAGNO also outperformed GPT-4o baseline and DeepSeek R1 across all top-k accuracy metrics. In a real-world evaluation on eight complex cases with differentials from Mass General Brigham, neurologists rated DIAGNO's reasoning favorably (mean 4.03/5) across multiple dimensions of clinical utility and safety. CONCLUSIONS NeuroBench establishes neuropathological confirmation as the appropriate standard for evaluating diagnostic AI in neurology, moving beyond clinician-referenced benchmarking to define the ceiling of diagnostic accuracy. Evaluated against this standard, DIAGNO achieved expert-level diagnostic performance and received favorable clinician ratings in real-world applications, supporting its potential as a clinical decision-support tool in neurology.

  • Open Access

    Single-Molecule Imaging Reveals Differential Stability of Alpha-Synuclein Aggregates

    by Shih-Chin Wang, Stephanie J. Zhang, Tal Gilboa, John Kang, Anastasia Kuzkina, George T Kannarkat, Liangxiao Chen, William M Shih, Alice S Chen-Plotkin, Vikram Khurana, et al.

    Alpha–Synuclein (α–syn) aggregation is central to Parkinson′s disease (PD), yet measurements in biofluids are confounded by the coexistence of monomeric and aggregated species. Using Syn–IMAGR, a single–molecule imaging platform with sub–femtomolar sensitivity, we show that purified α–syn aggregates undergo dilution–induced disassembly, revealing a concentration–dependent equilibrium. Applied to postmortem brain lysates, Syn–IMAGR distinguishes physiological α–syn multimers, which are dimmer and readily dissociate upon dilution, from PD–associated aggregates, which remain detectable and exhibit greater structural resistance to disruption. These results indicate that α–syn assemblies occupy distinct stability regimes, with PD–associated aggregates representing a more persistent and less dilution–sensitive structural state. Syn–IMAGR thus provides a quantitative framework for resolving α–syn species and for probing their concentration–dependent equilibrium.

  • Open Access

    NERINE reveals rare variant associations in gene networks across phenotypes and implicates an SNCA-PRL-LRRK2 subnetwork in Parkinson’s disease

    by Sumaiya Nazeen, Xinyuan Wang, Autumn R. Morrow, Ronya Strom, Elizabeth Ethier, Dylan Ritter, Alexander B.H. Henderson, Jalwa Afroz, Christopher S. Cassa, Nathan O. Stitziel, et al.


  • Open Access

    tRNA-derived fragments are elevated in the aging brain and may contribute to neurodegeneration

    by Lien D. Nguyen, Ami Kobayashi, Alain Ndayisaba, Vikram Khurana, Pavel Ivanov, Anna M. Krichevsky

    TRNA-derived fragments (tRFs) are a class of small noncoding RNAs with emerging roles in stress responses and gene regulation, yet their dynamics across tissues and brain regions during aging remain poorly understood. Here, we systematically profiled age-associated changes in tRFs using three independent mouse small RNA-seq datasets spanning multiple organs and brain regions. Nuclear-encoded tRFs were the only small RNA class showing a strong, progressive accumulation with age, a pattern that was specific to the brain and broadly distributed across brain regions. Fragment length distributions, boundary profiles, and coverage maps were consistent with amplified cleavage at conserved sites, implicating angiogenin as a primary driver. Age-associated increases in specific tRF species, including 5’Cys GCA , 5’Glu CTC , and 5’Gly GCC , were validated by northern blotting and RT-qPCR. Analogous upregulation was observed in human frontal lobe tissue from frontotemporal dementia patients and in cerebrospinal fluid from traumatic brain injury patients, suggesting that tRF accumulation is further amplified under neurological stress. Together, these findings establish nuclear-encoded tRFs as a small RNA class that accumulates selectively in the aging brain, with potential roles in neurodegeneration, and as biomarkers and targets for therapeutic intervention.

  • Open Access

    A case report of multiple system atrophy-mimics: Importance of comprehensive evaluation in suspected familial cases

    by Chanhee Jeong, Matthew Farrer, Vikram Khurana, Han-Joon Kim

    Rationale: Multiple system atrophy (MSA) is primarily a sporadic neurodegenerative disorder, and a positive family history is considered against the diagnosis. While rare familial clusters are reported, they pose a significant diagnostic challenge. This report describes 2 cousins with phenotypically classic MSA who underwent genetic testing to investigate a potential shared etiology, leading to a diagnosis of a rare MSA mimic. Patient concerns: Case 1: a 77-year-old male presented with Parkinsonism (bradykinesia, resting tremor) and neurogenic orthostatic hypotension. Case 2: a 55-year-old female, case 1’s 1st cousin, presented with progressive limb ataxia, dysarthria, and neurogenic orthostatic hypotension. Both patients reported a poor therapeutic response to levodopa and a progressive decline in functional mobility. Diagnoses: Initially, case 1 was diagnosed with clinically probable MSA with predominant Parkinsonism, and case 2 was diagnosed with clinically probable MSA with predominant cerebellar ataxia (MSA-C). However, post-genetic analysis, case 1 was definitively diagnosed with late-onset metachromatic leukodystrophy (MLD). Case 2 remained clinically classified as MSA-C as no significant genetic variants were identified. Interventions: Clinical evaluation and levodopa trials were conducted for both patients. To investigate the suspected familial MSA cluster, whole-genome sequencing was performed for both individuals to identify shared pathogenic variants. Outcomes: Whole-genome sequencing identified biallelic pathogenic mutations in the arylsulfatase A gene in case 1, confirming MLD. No shared genetic etiology was found in case 2. The discovery of MLD in case 1 provided an alternative metabolic explanation for his symptoms, thereby refuting the initial hypothesis of a shared familial MSA link between the 2 cousins. Lessons: This case highlights that late-onset MLD can closely mimic the clinical phenotype of MSA. Clinicians should maintain a high index of suspicion when encountering familial MSA. A comprehensive genetic evaluation is essential in such cases to exclude metabolic or hereditary mimics before concluding a rare familial presentation of a typically sporadic synucleinopathy.

  • Open Access

    Skin Seed Amplification Assay differentiates Multiple System Atrophy from Parkinson’s Disease

    by Anastasia Kuzkina, Diego Rodriguez, Celine Panzer, Alain Ndayisaba, Antonia Kohl, Shreya Rai, Karie Shen, Lisa Harder-Rauschenberger, Olivia Laun, Julia Meehan, et al.

    Background: Misdiagnoses of multiple system atrophy (MSA) and Parkinson’s disease (PD) remain common due to overlapping clinical features. Objective: To develop and assess a skin α-synuclein seed amplification assay (αSyn-SAA) for detecting pathological α-synuclein and distinguishing MSA from PD. Methods: In this blinded, cross-sectional study conducted across two laboratories, 308 skin biopsies from 117 participants were analyzed using a standardized αSyn-SAA protocol. The cohort included 42 PD, 31 MSA, 30 controls, and 14 with progressive supranuclear palsy (PSP). Biopsies were obtained from up to four anatomical sites and positivity was defined as ≥75% positive replicates. Kinetic parameters were analyzed to differentiate PD and MSA, and clinical features were correlated with αSyn-SAA positivity. Fibril morphology from amplified skin samples was compared to postmortem brain using proteinase K digestion and electron microscopy. Results: αSyn-SAA detected synucleinopathy in 86% of PD and 77% of MSA patients, with 90% specificity versus controls and 86% versus PSP. ROC analysis showed that maximum fluorescence (Fmax, AUC = 0.93) and lag time (AUC = 0.91) distinguished PD from MSA at the biopsy level. A 50% mean Fmax cutoff across positive samples accurately differentiated synucleinopathies with 90% sensitivity and 85% specificity. αSyn-SAA positivity correlated with RBD in both disorders and with autonomic features in MSA. Amplified fibrils displayed distinct structural and proteolytic profiles between PD and MSA, consistent with brain-derived aggregates. Conclusion: Skin αSyn-SAA detects pathological α-synuclein in living patients with high accuracy and distinguishes MSA from PD based on assay kinetics and fibril strain properties.

  • Open Access

    Graph AI generates neurological hypotheses validated in molecular, organoid, and clinical systems

    by Ayush Noori, Joaquín Polonuer, Katharina Meyer, Bogdan Budnik, Shad Morton, Xinyuan Wang, Sumaiya Nazeen, Yingnan He, Iñaki Arango, Lucas Vittor, et al.

    Neurological diseases are the leading global cause of disability, yet most lack disease-modifying treatments. We present PROTON, a heterogeneous graph transformer that generates testable hypotheses across molecular, organoid, and clinical systems. To evaluate PROTON, we apply it to Parkinson's disease (PD), bipolar disorder (BD), and Alzheimer's disease (AD). In PD, PROTON linked genetic risk loci to genes essential for dopaminergic neuron survival and predicted pesticides toxic to patient-derived neurons, including the insecticide endosulfan, which ranked within the top 1.29% of predictions. In silico screens performed by PROTON reproduced six genome-wide $α$-synuclein experiments, including a split-ubiquitin yeast two-hybrid system (normalized enrichment score [NES] = 2.30, FDR-adjusted $p < 1 \times 10^{-4}$), an ascorbate peroxidase proximity labeling assay (NES = 2.16, FDR $< 1 \times 10^{-4}$), and a high-depth targeted exome sequencing study in 496 synucleinopathy patients (NES = 2.13, FDR $< 1 \times 10^{-4}$). In BD, PROTON predicted calcitriol as a candidate drug that reversed proteomic alterations observed in cortical organoids derived from BD patients. In AD, we evaluated PROTON predictions in health records from $n = 610,524$ patients at Mass General Brigham, confirming that five PROTON-predicted drugs were associated with reduced seven-year dementia risk (minimum hazard ratio = 0.63, 95% CI: 0.53-0.75, $p < 1 \times 10^{-7}$). PROTON generated neurological hypotheses that were evaluated across molecular, organoid, and clinical systems, defining a path for AI-driven discovery in neurological disease.

  • Open Access

    A single-cell genetic colocalization test improves power and resolves disease-mediating cell types

    by Jonathan Mitchel, Sumaiya Nazeen, Xinyuan Wang, Praveen Kumar Patnaik, Autumn Morrow, Habib Nasir, Ronya Strom, Dylan Ritter, Lorenz Studer, Sung Chun, et al.

    Statistical colocalization testing methods can determine if the same single-nucleotide polymorphism (SNP) underlies both a genome-wide association study (GWAS) locus as well as an expression quantitative trait (eQTL) locus. This can nominate potential mechanistic pathways from SNPs to genes to traits, while providing cell type or tissue context. Surprisingly, systematic colocalization testing with bulk-tissue eQTLs fails to link the majority of GWAS loci with gene expression changes. Mapping eQTLs with single-cell expression data has the potential to reveal the missing regulatory effects of GWAS variants. However, current pseudobulk cluster-based approaches may be underpowered when clustering accuracy is imperfect or with an incorrectly selected cluster resolution. To improve power of single-cell colocalization tests, we developed a cluster-free method, scJLIM. By modeling eQTL interactions with continuous cell states (e.g., principal components), scJLIM estimates eQTL significance and colocalization in individual cells. We benchmarked our method with simulated data, demonstrating improvements in power over pseudobulk methods. In our main applications, we used scJLIM to analyze blood and brain scRNA-seq datasets paired with autoimmune and neurological disease GWAS, respectively. We identified nearly twice as many total colocalizations compared with traditional pseudobulk analyses carried out within the major cell populations of these tissues. Aligning with a recent experimental study, we highlighted an example of the ETS2 gene colocalizing with an inflammatory bowel disease GWAS locus in a subset of myeloid cells. For Parkinson’s disease (PD), our results pointed to TRPV2 as a potential gene of interest, corroborated by transcriptional changes in both post-mortem PD brains and iPSC-derived neuronal models of alpha-synucleinopathy.